奥氮平与氯氮平治疗难治性精神分裂症对照研究

A control study of olanzapine vs clozapine in the treatment of refractory schizophrenia.

目的评价奥氮平治疗难治性精神分裂症患者的临床疗效及安全性。方法将60例难治性精神分裂症患者随机分为奥氮平治疗组30例，氯氮平治疗组30例，疗程均为8月。治疗前及治疗第2、4、6、8个月末采用阳性与阴性症状量表（PANSS）评定临床疗效，副反应量表（TESS）及有关实验室检查评定不良反应。结果阳性与阴性症状量表（PANSS）评定治疗第2、4、6、8个月末与治疗前均有统计学意义（P〈0．05），两组间比较差异无统计学意义（P〉0．05）。奥氮平主要不良反应为轻度头晕、嗜睡、轻微的的胆碱作用等，氯氮平组为流涎、嗜睡、体重增加、恶心呕吐等。结论奥氮平治疗难治性精神分裂症疗效与氯氮平相当，不良反应较氯氮平轻微害今性垂高服端饭从乖僻，

Objective To explore the curative effect and safety of olanzapine in the treatment of refractory schizopherenia. Methods A total of 60 refactory schizopherenics were randomly divided into olanzapine （ n = 30） group and clozapine （ n = 30） group for the treatment of 8 months. The curative effect was assessed with PANSS, and side effects with TESS, and other experimental assessments before treatment and in the 2nd,4th,6th and 8th month after treatment. Results There were significant differences of PANSS and TESS between pre - treatment and each time section of treatment（ P 〈 0. 05 ）and no significant differences were found between the two groups（ P 〉 0. 05 ）. Conclusion Olanzapine has similar curative effect with clozapine, milder side effects and better compliance.